Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis

Jemma Hudson, Moira Cruickshank, Richard Quinton, Lorna Aucott, Frederick Wu, Mathis Grossmann, Shalender Bhasin, Peter J. Snyder, Susan S. Ellenberg, Thomas G. Travison, Gerald B. Brock, Emily J. Gianatti, Yvonne T. van der Schouw, Marielle H. Emmelot-Vonk, Erik J. Giltay, Geoff Hackett, Sudarshan Ramachandran, Johan Svartberg, Kerry L. Hildreth, Kristina Groti AntonicJoyce Lisa Tenover, Hui Meng Tan, Christopher Ho Chee Kong, Wei Shen Tan, Leonard S. Marks, Richard J. Ross, Robert S. Schwartz, Paul Manson, Stephen A. Roberts, Marianne Skovsager Andersen, Line Velling Magnussen, Magaly Aceves-Martins, Katie Gillies, Rodolfo Hernández, Nick Oliver, Waljit S. Dhillo, Siladitya Bhattacharya, Miriam Brazzelli, Channa N. Jayasena*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

29 Downloads (Pure)

Abstract

Background: Testosterone replacement therapy is known to improve sexual function in men younger than 40 years with pathological hypogonadism. However, the extent to which testosterone alleviates sexual dysfunction in older men and men with obesity is unclear, despite the fact that testosterone is being increasingly prescribed to these patient populations. We aimed to evaluate whether subgroups of men with low testosterone derive any symptomatic benefit from testosterone treatment. Methods: We did a systematic review and meta-analysis to evaluate characteristics associated with symptomatic benefit of testosterone treatment versus placebo in men aged 18 years and older with a baseline serum total testosterone concentration of less than 12 nmol/L. We searched major electronic databases (MEDLINE, Embase, Science Citation Index, and the Cochrane Central Register of Controlled Trials) and clinical trial registries for reports published in English between Jan 1, 1992, and Aug 27, 2018. Anonymised individual participant data were requested from the investigators of all identified trials. Primary (cardiovascular) outcomes from this analysis have been published previously. In this report, we present the secondary outcomes of sexual function, quality of life, and psychological outcomes at 12 months. We did a one-stage individual participant data meta-analysis with a random-effects linear regression model, and a two-stage meta-analysis integrating individual participant data with aggregated data from studies that did not provide individual participant data. This study is registered with PROSPERO, CRD42018111005. Findings: 9871 citations were identified through database searches. After exclusion of duplicates and publications not meeting inclusion criteria, 225 full texts were assessed for inclusion, of which 109 publications reporting 35 primary studies (with a total 5601 participants) were included. Of these, 17 trials provided individual participant data (3431 participants; median age 67 years [IQR 60–72]; 3281 [97%] of 3380 aged ≥40 years) Compared with placebo, testosterone treatment increased 15-item International Index of Erectile Function (IIEF-15) total score (mean difference 5·52 [95% CI 3·95–7·10]; τ2=1·17; n=1412) and IIEF-15 erectile function subscore (2·14 [1·40–2·89]; τ2=0·64; n=1436), reaching the minimal clinically important difference for mild erectile dysfunction. These effects were not found to be dependent on participant age, obesity, presence of diabetes, or baseline serum total testosterone. However, absolute IIEF-15 scores reached during testosterone treatment were subject to thresholds in patient age and baseline serum total testosterone. Testosterone significantly improved Aging Males’ Symptoms score, and some 12-item or 36-item Short Form Survey quality of life subscores compared with placebo, but it did not significantly improve psychological symptoms (measured by Beck Depression Inventory). Interpretation: In men aged 40 years or older with baseline serum testosterone of less than 12 nmol/L, short-to-medium-term testosterone treatment could provide clinically meaningful treatment for mild erectile dysfunction, irrespective of patient age, obesity, or degree of low testosterone. However, due to more severe baseline symptoms, the absolute level of sexual function reached during testosterone treatment might be lower in older men and men with obesity. Funding: National Institute for Health and Care Research Health Technology Assessment Programme.

Original languageEnglish
JournalThe Lancet Healthy Longevity
Volume4
Issue number10
Pages (from-to)e561-e572
ISSN2666-7568
DOIs
Publication statusPublished - Oct 2023

Fingerprint

Dive into the research topics of 'Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis'. Together they form a unique fingerprint.

Cite this